ClinicalTrials.gg
RecruitingNCT02754115Updated Nov 21, 2024

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

An observational study in Colorectal Cancer, Ovarian Cancer and Peritoneal Disease, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Tata Memorial Centre · Observational

How we know

From the registry’s dates

  • Started Apr 2016; still recruiting 10 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Colorectal Neoplasms with a site in India — 8 open to participants now, 13 under way, 7 of them phase 3. Colorectal Neoplasms · India.

Started
2016
the only one that year
Observational
5 of 33
2 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
19th of 33
by date

Among the 33 studies in Colorectal Neoplasms with a site in India, this one is the only one that started in 2016, is one of 5 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 19th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

8 of the 33 studies in Colorectal Neoplasms with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Colorectal Neoplasms with a site in India, or all of them as a file.
02

Study summary

Peritoneal carcinomatosis is a common event in the natural history of colorectal and other digestive tract cancers. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising therapeutic option for highly selected patients with peritoneal carcinomatosis arising from different malignancies such as colorectal cancer, gastric cancer, ovarian cancer, or peritoneal mesothelioma with improvement of both patient survival and quality of life. CRS, i.e., removal of all visible metastatic abdominal and pelvic disease with peritonectomy along with HIPEC (for 90 min at a temperature of 42º C) and/or early postoperative intraperitoneal chemotherapy (EPIC) in order to eradicate all microscopic metastasis.

CRS with HIPEC is a long and complex procedure with significant blood and fluid loss during debulking, hemodynamic, hematological, and metabolic alterations before and during the HIPEC phase, and even in the early postoperative period, with resultant significant morbidity and mortality. Despite that most of the reported patients are in American Society of Anesthesiologist class I and II, without significant comorbidities or systemic disorder; the morbidity and mortality ranges from 12 to 65% in these procedures, so a well coordinated team of anesthesiologist, surgeons and intensivist and other ancillary services can result in good outcome. This study will see the challenges faced by the team regarding the pathophysiological alterations during the CRS with HIPEC in the perioperative period.

03

Conditions studied

  • Colorectal Cancer
  • Ovarian Cancer
  • Peritoneal Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

American Society of Anesthesiologist class I, II and III patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 to 70 years
  2. ASA Class I to III
  3. Colorectal and gynecological oncology cases posted for CRS with HIPC.

Exclusion criteria

Exclusion Criteria:

  1. Age less than 18 and more than 70 years
  2. ASA Class IV and above
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • OtherHyperthermic intraperitoneal chemotherapy

    Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively

06

What researchers measure

Primary outcomes

  1. Changes in invasive blood pressure in perioperative period

    Invasive blood pressure will be measured in radial artery in perioperative period and changes from baseline will be recorded in a graphical manner

    Time frame: From start of surgery upto 48 hours after surgery

  2. Changes in body temperature in perioperative period

    Body temperature will be measured in degree centigrade by nasopharyngeal temperature probe in perioperative period and changes from baseline will be recorded in a graphical manner

    Time frame: From start of surgery upto 48 hours after surgery

  3. Changes in cardiac output in perioperative period

    Cardiac output will be measured in perioperative period and changes from baseline will be recorded in a graphical manner

    Time frame: From start of surgery upto 48 hours after surgery

  4. Changes in arterial blood gas in perioperative period

    Arterial blood gases will be measured in perioperative period and changes from baseline will be recorded in a graphical manner

    Time frame: From start of surgery upto 48 hours after surgery

Secondary outcomes

  1. Length of stay in intensive care unit

    Length of stay will be measured in days from admission to discharge in intensive care unit

    Time frame: Upto 30 days after surgery

  2. Mortality

    30 days mortality will be noted if death occurred within this period

    Time frame: Upto 30 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2016 (actual). Primary completion is estimated for Dec 2026, 128 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 128 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 28, 2016
StartActual
Apr 2016
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02754115
Lead sponsor
Tata Memorial Centre
Responsible party
Sohan Lal Solanki (Assistant Professor, Department of Anesthesiology, Critical Care and Pain, Tata Memorial Centre) — Principal investigator
First posted
Apr 28, 2016
Start date
Apr 2016
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 21, 2024

Study contacts

Sohan L Solanki, MD
Contact
me_sohans@yahoo.co.in
+919869253201
Sohan L solanki
principal investigator · Tata Memorial Centre

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion